The estimated Net Worth of John P. Schmid is at least $1.21 Milione dollars as of 12 August 2024. Mr. Schmid owns over 4,515 units of AnaptysBio Inc stock worth over $897,120 and over the last 8 years he sold ANAB stock worth over $0. In addition, he makes $310,958 as Independent Director at AnaptysBio Inc.
Sign up
Mr. Schmid ANAB stock SEC Form 4 insiders trading
John has made over 6 trades of the AnaptysBio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 4,515 units of ANAB stock worth $10,159 on 12 August 2024.
The largest trade he's ever made was buying 6,500 units of AnaptysBio Inc stock on 16 November 2023 worth over $9,815. On average, John trades about 882 units every 8 days since 2016. As of 12 August 2024 he still owns at least 25,200 units of AnaptysBio Inc stock.
You can see the complete history of Mr. Schmid stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Schmid biography
John P. Schmid serves as Independent Director of the Company. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co-founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003, and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of Neos Therapeutics, Poseida Therapeutics, Xeris Pharmaceuticals and Forge Therapeutics, all pharmaceutical companies, and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University. Our board of directors believes that Mr. Schmid’s extensive industry experience and executive positions at multiple biopharmaceutical companies qualify him to serve on our board of directors.
What is the salary of John Schmid?
As the Independent Director of AnaptysBio Inc, the total compensation of John Schmid at AnaptysBio Inc is $310,958. There are 9 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.
How old is John Schmid?
John Schmid is 57, he's been the Independent Director of AnaptysBio Inc since 2015. There are 7 older and 6 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.
What's John Schmid's mailing address?
John's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.
Insiders trading at AnaptysBio Inc
Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 e James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.
What does AnaptysBio Inc do?
founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
What does AnaptysBio Inc's logo look like?
Complete history of Mr. Schmid stock trades at AnaptysBio Inc, Neos Therapeutics Inc, Xeris Biopharma Inc e Poseida Therapeutics
AnaptysBio Inc executives and stock owners
AnaptysBio Inc executives and other stock owners filed with the SEC include:
-
Hamza Suria,
President, Chief Executive Officer, Director -
Eric Loumeau,
Chief Operating Officer, General Counsel -
Hamza Suria,
Pres, CEO & Director -
Dennis M. Mulroy,
Chief Financial Officer -
Dr. Paul F. Lizzul,
Chief Medical Officer -
James Topper,
Independent Chairman of the Board -
Dennis Fenton,
Independent Director -
Hollings Renton,
Lead Independent Director -
J. Anthony Ware,
Independent Director -
John Schmid,
Independent Director -
Laura Hamill,
Independent Director -
Paul Lizzul,
Chief Medical Officer -
Dennis Mulroy,
Chief Financial Officer -
Eric J. Loumeau,
COO & Gen. Counsel -
David McKeon,
VP & Controller -
Dr. Margaret Marino,
Sr. VP of Project Management -
Beth Mueller,
Sr. VP of HR -
Nicholas Lydon,
Director -
Carol Giltner Gallagher,
Director -
Matthew Moyle,
Chief Scientific Officer -
James A Schoeneck,
Director -
Dominic Piscitelli,
Chief Financial Officer -
Marco Londei,
Chief Medical Officer -
Healthcare Vii, L.P.Frazier...,
-
Healthcare V, Lpfhm V, Lpfh...,
-
Holdings A/S Novo,
10% owner -
Ventures Vii L Pavalon Vent...,
-
John A Orwin,
-
Magda Marquet,
-
Rita Jain,
-
Capital, Llcnodelman Oleg E...,
-
Capital, Llc Eco R1,
10% owner -
Daniel Faga,
CEO